NICE backs another indication for CAR-T therapy Kymriah

1 February 2019

Swiss pharma giant Novartis’ (NOVN: VX) CAR-T therapy Kymriah (tisagenlecleucel) has been approved by the UK’s cost-effectiveness watchdog the National Institute for Health and Care Excellence (NICE) for diffuse large B-cell lymphoma (DLBCL).

As a result, and following commercial agreement with NHS England, Kymriah will be available on the National Health Service (NHS) in England and Wales to eligible patients via the Cancer Drugs Fund.

This decision follows the previous approval for Kymriah by the NICE in September 2018 for pediatric and young adult patients up to 25 years of age with B-cell acute lymphoblastic leukemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK